Aerovate Therapeutics, Inc. Board of Directors

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Mr. Timothy P. Noyes M.B.A.

Mr. Timothy P. Noyes M.B.A.

CEO & Director

Dr. Cheryl Lassen BSc., M.D., MBBCh

Dr. Cheryl Lassen BSc., M.D., MBBCh

Senior Vice President of Clinical Development

Mr. Hunter Gillies M.D.

Mr. Hunter Gillies M.D.

Chief Medical Officer

Ms. Susan Fischer

Ms. Susan Fischer

Executive Vice President of Development Operations

Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S

Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S

Chief Scientific Officer

Dr. Sanjeev Khindri

Dr. Sanjeev Khindri

Executive Vice President of Clinical Development

Mr. Stephen K. Yu

Mr. Stephen K. Yu

Senior Vice President of Quality

Dr. Benjamin T. Dake Ph.D.

Dr. Benjamin T. Dake Ph.D.

Founder, President, COO & Secretary

Mr. George A. Eldridge

Mr. George A. Eldridge

CFO & Treasurer

Ms. Donna Dea

Ms. Donna Dea

Head of Regulatory Affairs

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments

Comment created.